Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Components (Tables)

v3.22.1
Balance Sheet Components (Tables)
3 Months Ended
Mar. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Components of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

 

 

March 31,

2022

 

 

December 31,

2021

 

Accrued liabilities:

 

 

 

 

 

 

 

 

General and administrative

 

$

1,160

 

 

$

794

 

Clinical trial related costs

 

 

615

 

 

 

1,134

 

Non-clinical research and manufacturing operations

 

 

3,418

 

 

 

2,153

 

Payroll related

 

 

2,660

 

 

 

5,388

 

Other accrued expenses

 

 

52

 

 

 

46

 

Total Accrued liabilities

 

$

7,905

 

 

$

9,515